You are here

Coronary Intervention & Surgery

 - Stent roundtable

A randomized trial in Spain found an everolimus-eluting stent (EES) was more effective than a drug-eluting balloon (DEB) in treating patients with drug-eluting stent in-stent restenosis. One year after the procedures, the primary endpoint of cardiac death, MI and target vessel revascularization occurred in 10 percent of the EES group and 18 percent of the DEB group. The difference was statistically significant.

 - Money down the drain

An intraprocedural thrombotic event in a patient with non-ST-segment elevation acute coronary syndromes (NSTEACS) adds approximately $3,600 to hospital costs, according to an economic analysis of the ACUITY trial that was published in the July issue of Catheterization and Cardiovascular Interventions.

 - Court - Law

The U.S. Department of Justice (DOJ) closed its investigation into Abiomed’s marketing of the Impella 2.5 device without taking any action against the company, according to an Abiomed news release on June 29.

 - thumbs up, approval, thumb

The FDA approved cangrelor on June 22 for adults undergoing PCI. The intravenous medication is an antiplatelet drug and is intended to prevent blood clots.

 - robot

Patients who underwent robotic-assisted cardiac surgery had significant reductions in length of hospital stay, complications and mortality compared with patients who received nonrobotic surgery. However, robotic-assisted cardiac surgery cost significantly more than nonrobotic options.

 

More Stories

Benefit-risk assessment tilts toward low-dose aspirin after PCI

An analysis of TRANSLATE-ACS data supports current guideline recommendations to prescribe low-dose aspirin to patients who underwent PCI and received dual antiplatelet therapy. The study was published online May 20 in Circulation.

PCI perplexities: Radial shunned despite bleeding advantage

Operators more often chose transfemoral over transradial PCI in a patients with higher predicted bleeding risks, despite evidence of fewer bleeding complications with the latter approach. Transfemoral PCI patients also tended to be sicker, according to this observational study.

Truly informed PCI patients

Sometimes a finding doesn’t reach the bar for statistical significance, but that doesn’t mean it isn’t intriguing. Interventional cardiologists might take note of a study on informed decision making that showed them more likely to touch on key elements than general cardiologists.

Informed patients more likely to opt against angiography, PCIs

Patients who were more fully informed about angiography and the possibility of PCI were more likely to decide against it, a study published online May 18 in JAMA Internal Medicine found. Overall, the cardiologist-patient discussions were short and incomplete.

Quitting smoking after PCI leads to quality of life improvements

More than a quarter of patients undergoing PCI are smokers at the time of treatment. If they quit smoking following the procedure, they are more likely to have improvements in quality of life and have less chest pain and angina than if they continue to smoke, according to a prospective analysis of a PCI registry.

Hospital traits may explain deficiencies in PCI rehab referrals

Only about 60 percent of PCI patients get referred to a cardiac rehabilitation program, according to a recent study, and the barrier is more likely due to hospital characteristics than insurance. 

SCAI.15: In practice, prasugrel use may not mimic trials

Cardiologists in real-world practice may not be optimizing the benefit of prasugrel in patients undergoing PCI but they also don’t appear to be putting them in harm’s way, according to results released May 8 at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 scientific session in San Diego.

SCAI.15: Orbital atherectomy sustains its benefits at 2 years

An atherectomy device that “sands” calcified lesions in coronary arteries before stenting proved to be effective and durable at two years, and possibly even cost-effective, in a late-breaking clinical trial unveiled on May 7.

GI events are most common bleeding complication 1 year after PCI

One year after patients underwent PCIs, approximately 1 percent had gastrointestinal bleeding, which was associated with an increased risk for all-cause mortality and the composite of death, MI or stroke.

Similar survival rates for children who receive therapeutic hypothermia or normothermia

Children who remained unconscious after out-of-hospital cardiac arrest had similar survival rates and cognitive functioning if they received therapeutic hypothermia or therapeutic normothermia, according to a randomized trial.

A safer cath lab

The cardiology community has heeded the call to protect patients from radiation exposure in the cath lab. Now it is time to focus on the operators and staff.

Synergy clears noninferiority bar in EVOLVE II

An everolimus-eluting stent with a bioresorbable coating held its own clinically against a durable polymer drug-eluting stent in the pivotal EVOLVE II trial, findings that may be used to determine regulatory approval of the bioresorbable device.

Diabetes patients undergoing CABG have increased risk of death

Patients with type 1 diabetes had double the risk of death after undergoing CABG compared with a group that did not have diabetes, according to an observational, nationwide population-based cohort study.

Potential harms from cath lab radiation may include heart disease

Interventional cardiologists and nurses worry about cardiovascular disease developing in their patients. A study that looked at long-term radiation exposure to cath lab operators and staff may prompt them to add themselves to that list.

OriGen Biomedical recalls ECMO catheters

OriGen Biomedical voluntarily recalled a lot of its 51 VV13F Reinforced Dual Lumen ECMO Catheters, according to the company and the FDA.

NIH launches largest trial to date for HIV-related cardiovascular disease

The NIH has launched a randomized, multicenter, international study to see if statins can reduce the risk of cardiovascular disease in HIV patients. As of now, no therapies have been found to lower cardiovascular risk in this patient population.

FDA advisory committee recommends approval of cangrelor

An FDA advisory panel recommended the approval of cangrelor to reduce the risk of periprocedural thrombotic events in patients with coronary artery disease undergoing PCI.

PROMETHEUS, ORBIT II, TRIAGE among SCAI's late-breakers

The Society for Cardiovascular Angiography and Interventions’ (SCAI) 2015 scientific session will flash some big names on its marque this year, with PROMETHEUS, ORBIT II and other trials scheduled to make an appearance.

Survey: Orthopedic injuries plague half of operators

Almost half of operators who responded to a survey on occupational health hazards in the cath lab reported they experienced at least one orthopedic injury, and more than one in 20 limited their case load because of radiation exposure.

Statement clarifies use of heart pumps in high-risk patients

Cardiologists trying to navigate the proper course of care for cardiac patients who might benefit from percutaneous mechanical circulatory support received a helping hand in the form of a consensus statement published online April 7. The document provides a roadmap for physicians until there is sufficient high-level evidence to inform guidelines.